Aldevron Breakthrough Blog
Presentation: Establishing a Sustainable Platform for CRISPR-Based Genome Editing Therapies
August 27, 2025 by Aldevron
An Academic-Industry Partnership Model for Addressing Inborn Errors of Immunity
When looking for solutions for problems, collaboration is a key to success, especially if the problem involves rare and ultra-rare diseases. And when the solution might be limited by costs and scientific complexity, partnerships become not just helpful, but essential.
For CRISPR-based genome editing therapies, the great promise they hold has been limited by these very barriers. As part of the solution to help overcome these challenges, Danaher Corporation and the Innovative Genomics Institute (IGI) began collaborating in 2024 to address these challenges by leveraging automation, quality control, and academic innovation.
During the ASGCT Annual Meeting earlier this year, Dr. Fyodor Urnov, Professor of Molecular Therapeutics at UC Berkeley and a Scientific Director at its Innovative Genomics Institute (IGI), and Dr. Sadik Kassim, Chief Technology Officer at Danaher, presented a novel, scalable platform for CRISPR therapies at ASGCT that targeted inborn errors of immunity (IEIs).
In this on-demand presentation, learn how gene editing advancements are accelerating therapeutic discovery and how integrated tools—from sample prep to data analysis—are streamlining research workflows. Urnov and Kassim walk through the platform technology and show how it’s designed to expand to other genes and diseases, aiming to make gene editing therapies more accessible.
Key Takeaways
- Discover how CRISPR is advancing functional genomics and cell therapy
- Learn how Danaher Life Sciences companies support the full CRISPR workflow
- Hear from IGI experts on real-world research applications
- Gain insights into emerging trends and technologies in genome editing
Their standardized cookbook supports academic-industry collaborations as a promising strategy to overcome the cost and timeline barriers limiting CRISPR’s full potential.
- Learn more about the world’s first mRNA-based personalized CRISPR therapy
- Meet Victoria Gray, the first person to have their cells edited with CRISPR technology, treating sickle cell disease
- Visit our CRISPR RNP-Based Genome Editing page
- Have questions on this topic? Contact Us
- Have an idea for a topic? Let us know!
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. You can follow the company on LinkedIn, Facebook and YouTube.